Your search history is turned on.
Date: May 2, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, LICHTENWALD, Konstantin, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised ...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario, Yukon
1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Konstantin Lichtenwald, Chief Financial Officer of BioCure Technology Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated ...
1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Simon Cheng, Chief Executive Officer of BioCure Technology Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by referenc...
1 BIOCURE TECHNOLOGY INC. Managements Discussion & Analysis As at December 31, 2023 INTRODUCTION The following managements discussion and analysis (MD&A) is a review of operations, current financial position and outlook for the Company and is performed by management using the information available as at May 2, 2024. ...
BIOCURE TECHNOLOGY INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 (Expressed in Canadian Dollars) Independent Auditor's Report To the Shareholders of Biocure Technology Inc. Opinion We have audited the consolidated financial statem...
Date: March 27, 2024 Jurisdictions: Alberta, British Columbia, Ontario, Yukon
News Release March 26, 2024 FOR IMMEDIATE RELEASE Biocure Technology Inc (CURE) Provides Update on Transaction with Atriva Therapeutics VANCOUVER, British Columbia, March 26, 2024 -- Biocure Technology Inc. (CURE or the Company) (CSE:CURE) is pleased to provide an update on its previously announced fundamental change transaction (the Transacti...
Date: December 1, 2023 Jurisdictions: Alberta, British Columbia, Ontario, Yukon
Form 51-102F3 Form 51-102F3 Material Change Report Item 1 Name and Address of Company Biocure Technology Inc. (the Company) 950-1130 West Pender Street Vancouver, B.C. V6E 4A4 Item 2 Date of Material Change November 24, 2023 Item 3 News Release A news release was disseminated on November 24, 2023 through...
Date: December 1, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: November 27, 2023 Jurisdictions: Alberta, British Columbia, Ontario, Yukon
Form 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Konstantin Lichtenwald, Chief Financial Officer of Biocure Technology Inc, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the (interim filings) of Biocure Technology Inc. (the issuer) for the...